Axonics Modulation Technologies Inc (NASDAQ:AXNX) COO Rinda Sama sold 13,345 shares of Axonics Modulation Technologies stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $28.03, for a total transaction of $374,060.35. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
AXNX opened at $31.73 on Thursday. The company has a market cap of $896.88 million and a PE ratio of -6.84. Axonics Modulation Technologies Inc has a 52-week low of $11.95 and a 52-week high of $32.90. The company has a debt-to-equity ratio of 0.16, a quick ratio of 22.07 and a current ratio of 22.83.
Axonics Modulation Technologies (NASDAQ:AXNX) last posted its quarterly earnings data on Tuesday, March 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.18). The firm had revenue of $0.49 million for the quarter, compared to the consensus estimate of $0.24 million. Equities research analysts predict that Axonics Modulation Technologies Inc will post -2.01 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC purchased a new stake in shares of Axonics Modulation Technologies during the fourth quarter valued at approximately $24,942,000. RTW Investments LP purchased a new stake in shares of Axonics Modulation Technologies during the fourth quarter valued at approximately $16,551,000. Millennium Management LLC purchased a new stake in shares of Axonics Modulation Technologies during the fourth quarter valued at approximately $12,072,000. Perceptive Advisors LLC purchased a new stake in shares of Axonics Modulation Technologies during the fourth quarter valued at approximately $10,935,000. Finally, BlackRock Inc. raised its stake in shares of Axonics Modulation Technologies by 17.2% during the first quarter. BlackRock Inc. now owns 388,922 shares of the company’s stock valued at $9,316,000 after purchasing an additional 57,052 shares during the period. Institutional investors own 31.36% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Axonics Modulation Technologies Inc (AXNX) COO Rinda Sama Sells 13,345 Shares” was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/05/16/axonics-modulation-technologies-inc-axnx-coo-rinda-sama-sells-13345-shares.html.
About Axonics Modulation Technologies
Axonics Modulation Technologies, Inc, a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention.
Further Reading: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for Axonics Modulation Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics Modulation Technologies and related companies with MarketBeat.com's FREE daily email newsletter.